Trabectedin and irinotecan combination regresses a cisplatinum-resistant osteosarcoma in a patient-derived orthotopic xenograft nude-mouse model-Reference-Cited by-同舟云学术

Trabectedin and irinotecan combination regresses a cisplatinum-resistant osteosarcoma in a patient-derived orthotopic xenograft nude-mouse model

Published:2019-05 Issue:2 Volume:513 Page:326-331
ISSN:0006-291X
Container-title:Biochemical and Biophysical Research Communications
language:en
Short-container-title:Biochemical and Biophysical Research Communications

Author:

Higuchi Takashi^ORCID,Miyake Kentaro^ORCID,Oshiro Hiromichi,Sugisawa Norihiko,Yamamoto Norio,Hayashi Katsuhiro,Kimura Hiroaki,Miwa Shinji,Igarashi Kentaro,Chawla Sant P.,Bouvet Michael,Singh Shree Ram^ORCID,Tsuchiya Hiroyuki,Hoffman Robert M.

Publisher

Elsevier BV

Subject

Cell Biology,Molecular Biology,Biochemistry,Biophysics

Reference29 articles.

1. Osteosarcoma: review of the past, impact on the future. The American experience;Jaffe;Cancer Treat Res.,2009

2. Osteosarcoma: a comprehensive review;Misaghi;SICOT J,2018

3. Current therapeutic strategies and novel approaches in osteosarcoma;Ando;Cancers,2013

4. Osteosarcoma: current treatment and a collaborative pathway to success;Isakoff;J. Clin. Oncol.,2015

5. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide;Bacci;Ann. Oncol.,2003

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Groenlandicine enhances cisplatin sensitivity in cisplatin-resistant osteosarcoma cells through the BAX/Bcl-2/Caspase-9/Caspase-3 pathway;Journal of Bone Oncology;2024-10

2. Current approaches in tissue engineering-based nanotherapeutics for osteosarcoma treatment;Biomedical Materials;2024-02-26

3. Trabectedin and Lurbinectedin Modulate the Interplay between Cells in the Tumour Microenvironment—Progresses in Their Use in Combined Cancer Therapy;Molecules;2024-01-09

4. Isovalerylspiramycin I inhibits proliferation, migration and invasion of osteosarcoma cells by targeting Topoisomerase 1 and suppressing the ataxia telangiectasia and Rad3‐related/checkpoint kinase 1 pathway;Clinical and Translational Discovery;2023-07-20

5. NEDDylated Cullin 3 mediates the adaptive response to topoisomerase 1 inhibitors;Science Advances;2022-12-09